Previously, Mui et al. reported an ongoing investigator-initiated randomized, double-blinded, placebo-controlled phase 2 clinical trial with a recombinant human Annexin A5 (SY-005) in patients with sepsis and COVID-19 [26]. The gene discussed is ANXA5; the disease is Sepsis.